Literature DB >> 21086534

Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review.

A de Jonghe1, J C Korevaar, B C van Munster, S E de Rooij.   

Abstract

OBJECTIVE: Circadian rhythm disturbances, like sundowning, are seen in dementia. Because the circadian rhythm is regulated by the biological clock, melatonin might be effective in the treatment of these disturbances. We systematically studied the effect of melatonin treatment in patients with dementia. In addition, we elaborate on the possible effects one might expect of melatonin treatment in patients with delirium, since dementia and delirium are strongly related. Moreover, some evidence exists that sundowning in patients with dementia and the alterations in the sleep/wake cycle, seen in patients with delirium both originate from circadian rhythm disturbances.
DESIGN: A systematic search of the literature, published between 1985 and April 2009, was performed using PubMed and other databases. All papers on melatonin treatment in dementia were retrieved. Effects of melatonin on circadian rhythm disturbances were scored by means of scoring sundowning/agitated behaviour, sleep quality and daytime functioning.
RESULTS: Nine papers, including four randomised controlled trials (RCTs) (n = 243), and five case series (n = 87) were reviewed. Two of the RCTs found a significant improvement on sundowning/agitated behaviour. All five case series found an improvement. The results on sleep quality and daytime functioning were inconclusive.
CONCLUSION: Sundowning/agitated behaviour improves with melatonin treatment in patients with dementia. There are several arguments that sundowning in patients with dementia and the alterations in the sleep/wake cycle in patients with delirium have a common background, namely a disturbance of the circadian rhythm. This suggests that melatonin treatment could also have the same positive effects in patients with delirium.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21086534     DOI: 10.1002/gps.2454

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  32 in total

Review 1.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

3.  Adjunctive treatment with melatonin receptor agonists for older delirious patients with the sundowning phenomenon.

Authors:  Ta-Chuan Yeh; Chin-Bin Yeh; Nian-Sheng Tzeng; Wei-Chung Mao
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

4.  The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial.

Authors:  Annemarieke de Jonghe; Barbara C van Munster; Hannah E van Oosten; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel M Levi; Joke C Korevaar; Sophia E de Rooij
Journal:  BMC Geriatr       Date:  2011-07-05       Impact factor: 3.921

5.  Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials.

Authors:  Sheng Chen; LiGen Shi; Feng Liang; Liang Xu; Doycheva Desislava; Qun Wu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-07-21       Impact factor: 5.590

6.  Sleep quality and its association with delirium among veterans enrolled in hospice.

Authors:  Christopher G Slatore; Elizabeth R Goy; Daniel J Oʼhearn; Eilis A Boudreau; Jean P OʼMalley; Dawn Peters; Linda Ganzini
Journal:  Am J Geriatr Psychiatry       Date:  2012-04       Impact factor: 4.105

7.  Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice.

Authors:  Tracy A Bedrosian; Kamillya L Herring; Zachary M Weil; Randy J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

8.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 9.  Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.

Authors:  Esmée M S Vural; Barbara C van Munster; Sophia E de Rooij
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

10.  Medical hypothesis: Light at night is a factor worth considering in critical care units.

Authors:  Randy J Nelson; A Courtney DeVries
Journal:  Adv Integr Med       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.